Bian Zheng, Ji Wei, Xu Bing, Huang Weiyi, Jiao Jiantong, Shao Junfei, Zhang Xiaolu
Department of Neurosurgery, Wuxi People's Hospital of Nanjing Medical University, Wuxi, Jiangsu 214000, P.R. China.
Mol Clin Oncol. 2020 Nov;13(5):45. doi: 10.3892/mco.2020.2115. Epub 2020 Aug 13.
Long non-coding RNAs (lncRNAs) have been demonstrated to serve important roles in a variety of human tumor types. The lncRNA small nucleolar RNA host gene 7 (SNHG7) is associated with a variety of cancer types, such as esophageal cancer, breast cancer and gastric neoplasia. Based on previous studies that examined SNHG7 expression in tumors, it has become clear that SNHG7 modulates tumorigenesis and cancer progression by acting as a competing endogenous RNA. SNHG7 can sponge tumor-suppressive microRNAs and regulate downstream signaling pathways. In addition, overexpression of SNHG7 is associated with the clinical characteristics of patients with cancer by regulating cellular proliferation, invasion and metastasis and by inhibiting apoptosis via a variety of mechanisms of action. The function of SNHG7 in tumorigenesis and cancer progression indicates that it can potentially act as a novel therapeutic target or a diagnostic biomarker for cancer therapy or detection, respectively.
长链非编码RNA（lncRNAs）已被证明在多种人类肿瘤类型中发挥重要作用。长链非编码RNA小核仁RNA宿主基因7（SNHG7）与多种癌症类型相关，如食管癌、乳腺癌和胃肿瘤。基于先前检测肿瘤中SNHG7表达的研究，很明显SNHG7通过作为竞争性内源RNA来调节肿瘤发生和癌症进展。SNHG7可以吸附肿瘤抑制性微小RNA并调节下游信号通路。此外，SNHG7的过表达通过调节细胞增殖、侵袭和转移以及通过多种作用机制抑制细胞凋亡，与癌症患者的临床特征相关。SNHG7在肿瘤发生和癌症进展中的作用表明，它有可能分别作为癌症治疗的新型治疗靶点或癌症检测的诊断生物标志物。
